盆腔恶性肿瘤一直对全球健康构成重大挑战，对男性人口的福祉产生不利影响。预计临床医生将在实践中继续面对这些癌症。纳米医学提供了有前景的策略，通过提供精确的递送方法来彻底改变男性盆腔恶性肿瘤的治疗，旨在提高治疗效果，同时最大限度地减少副作用。纳米颗粒旨在封装治疗剂并选择性地靶向癌细胞。它们还可以装载治疗诊断剂，实现多功能功能。本综述旨在总结最新的纳米医学研究在临床应用中的应用，重点关注基于纳米技术的男性盆腔恶性肿瘤的治疗策略，包括化疗、放疗、免疫治疗等前沿技术疗法。该综述的目的是帮助医生，特别是那些生物化学和生物工程知识有限的医生理解纳米材料的功能和应用。利用包括 PubMed、国家医学图书馆和 Embase 在内的多个数据库来查找和审查最近发表的关于前列腺癌和结直肠癌纳米药物输送进展的文章。纳米医学在改善男性盆腔恶性肿瘤的治疗效果和减少不良反应方面具有巨大的潜力。通过精确的递送方法，这个新兴领域提供了创新的治疗方式来解决这些具有挑战性的疾病。然而，目前大多数研究都处于临床前阶段，缺乏足够的证据来充分理解确切的作用机制，缺乏全面的药毒性特征，并且长期后果存在不确定性。版权所有 © 2024 作者。由爱思唯尔公司出版。保留所有权利。

Pelvic malignancies consistently pose significant global health challenges, adversely affecting the well-being of the male population. It is anticipated that clinicians will continue to confront these cancers in their practice. Nanomedicine offers promising strategies that revolutionize the treatment of male pelvic malignancies by providing precise delivery methods that aim to improve the efficacy of therapeutic outcomes while minimizing side effects. Nanoparticles are designed to encapsulate therapeutic agents and selectively target cancer cells. They can also be loaded with theragnostic agents, enabling multifunctional capabilities.This review aims to summarize the latest nanomedicine research into clinical applications, focusing on nanotechnology-based treatment strategies for male pelvic malignancies, encompassing chemotherapy, radiotherapy, immunotherapy, and other cutting-edge therapies. The review is structured to assist physicians, particularly those with limited knowledge of biochemistry and bioengineering, in comprehending the functionalities and applications of nanomaterials.Multiple databases, including PubMed, the National Library of Medicine, and Embase, were utilized to locate and review recently published articles on advancements in nano-drug delivery for prostate and colorectal cancers.Nanomedicine possesses considerable potential in improving therapeutic outcomes and reducing adverse effects for male pelvic malignancies. Through precision delivery methods, this emerging field presents innovative treatment modalities to address these challenging diseases. Nevertheless, the majority of current studies are in the preclinical phase, with a lack of sufficient evidence to fully understand the precise mechanisms of action, absence of comprehensive pharmacotoxicity profiles, and uncertainty surrounding long-term consequences.Copyright © 2024 The Author(s). Published by Elsevier Inc. All rights reserved.